中泰证券股份有限公司与关联财务公司 开展金融业务风险处置预案 第一章 总 则 第一条 为有效防范、及时控制和化解中泰证券股份有限公司(以下简 称公司)及控股子公司与存在关联关系（定义见《上海证券交易所股票上 市规则》）的财务公司(以下简称关联财务公司)开展金融业务的风险，保 障资金安全，根据《企业集团财务公司管理办法》《关于规范上市公司与 企业集团财务公司业务往来的通知》《上海证券交易所股票上市规则》《上 海证券交易所上市公司自律监管指引第 5 号——交易与关联交易》等有关 规定，制定本风险处置预案。 第二条 公司与关联财务公司发生业务往来，应当遵循平等自愿原则， 保障公司的独立性。公司不得通过关联交易套取资金，不得隐匿违规关联 交易或通过关联交易隐匿资金真实去向、从事违法违规活动。 第二章 组织机构及职责 第三条 公司成立关联财务公司金融业务风险防范及处置工作组(简 称财务公司风险处置工作组）,负责组织开展相关金融业务风险的防范和 处置工作。 第四条 财务公司风险处置工作组由公司首席风险官任组长，成员包 括公司风险管理部、合规管理总部、法律事务部、计划财务总部、企业文 1 化部及相关业务单位负责人。 第五条 ...

证券代码：600918 证券简称：中泰证券 公告编号：2025-014 中泰证券股份有限公司 关于与山东能源集团财务有限公司签署关联交易协议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、日常关联交易基本情况 （一）日常关联交易履行的审议程序 公司拟与山东能源集团财务有限公司（以下简称"山能财司"）开展日常 关联交易，为其提供认购/申购公司代销的货币基金及相关服务。2025年4月29 日，公司第三届董事会第十一次会议审议并全票通过《关于公司与山东能源集 团财务有限公司签署关联交易协议的议案》，关联董事茹刚、谢蛟龙回避表决。 该议案事先经公司第三届董事会风险管理委员会、审计委员会、独立董事专门 会议审议通过。 截至2024年末，公司经审计的归属于母公司所有者权益为427.22亿元。本 次关联交易各年度交易上限达到公司归属于母公司所有者权益的5%，根据《上 海证券交易所股票上市规则》《上海证券交易所上市公司自律监管指引第5号— —交易与关联交易》及《公司章程》《公司关联交易管理制度》的规定，本次 关联交 ...

中泰证券4月29日晚间公告，拟3亿元—5亿元回购公司股份，用于减少注册资本，回购价格不超过9.42 元/股。 ...

智通财经4月29日电，中泰证券(600918.SH)公告称，公司拟使用自有资金以集中竞价交易方式回购部分 公司股份，回购的股份将用于减少公司注册资本。回购金额不低于3亿元且不超过5亿元，回购价格不超 过9.42元/股。回购期限自股东会审议通过回购方案之日起3个月内。 中泰证券：拟3亿元-5亿元回购股份 用于减少注册资本 ...

Group 1 - The core viewpoint of the announcement is that Zhongtai Securities reported a revenue of 2.545 billion yuan for the first quarter of 2025, reflecting a year-on-year growth of 0.23% [1] - The net profit for the same period was 370 million yuan, showing a year-on-year increase of 11.61% [1]

Core Insights - The main contract of the CSI 1000 Index futures closed at 2506, with a change of +0.70% and a trading volume of 116,200 contracts as of April 29 [1][2] - Total trading volume for all contracts was 178,800 contracts, a decrease of 9,018 contracts from the previous day [1][4] - The top 20 positions showed a net short position with a difference of 17,010 contracts [1] Group 1: Trading Volume and Positions - The total long positions for the top 20 contracts were 219,500 contracts, down by 3,655 contracts from the previous day [1][4] - The total short positions for the top 20 contracts were 247,900 contracts, down by 2,709 contracts from the previous day [1][4] - The top three long positions were held by Guotai Junan (45,437 contracts), CITIC Futures (41,114 contracts), and Guotou Futures (13,619 contracts) [1][4] Group 2: Changes in Long and Short Positions - The top three increases in long positions were from Guotai Junan (22,105 contracts, +1,074), CITIC Futures (21,092 contracts, +552), and Donghai Futures (2,214 contracts, +284) [1][3] - The top three decreases in long positions were from Zhongtai Futures (4,891 contracts, -466), Guoxin Futures (2,611 contracts, -376), and Huatai Futures (4,035 contracts, -279) [1][3] - The top three increases in short positions were from Guotai Junan (17,974 contracts, +657), Huawen Futures (2,969 contracts, +617), and Guoxin Futures (4,713 contracts, +371) [1][3] - The top three decreases in short positions were from Zhongtai Futures (2,971 contracts, -297), Galaxy Futures (4,399 contracts, -155), and Yong'an Futures (2,080 contracts, -150) [1][3]

Core Viewpoint - Jiangsu Lihua Food Group Co., Ltd. successfully issued 55,922,501 shares at a price of RMB 22.71 per share, raising a total of approximately RMB 1.27 billion, with a net amount of approximately RMB 1.26 billion after deducting related fees [1][2]. Group 1: Fundraising Details - The issuance was approved by the China Securities Regulatory Commission and listed on the Shenzhen Stock Exchange on August 31, 2022 [2]. - The net proceeds from the fundraising amounted to RMB 1,260,644,075.21 after deducting underwriting and other related expenses [1]. Group 2: Sponsorship and Oversight - Zhongtai Securities acted as the sponsor for the issuance and will continue its supervisory responsibilities until December 31, 2024 [2]. - The sponsor committed to ensuring the accuracy and completeness of the report and accepted regulatory inquiries from the CSRC [2]. Group 3: Due Diligence and Compliance - During the due diligence phase, the company cooperated with the sponsor by providing necessary documents and information for the issuance process [6]. - The company has adhered to regulatory requirements for information disclosure and operational compliance during the ongoing supervision phase [8]. Group 4: Changes in Fund Usage - On August 4, 2023, the company announced changes to its fundraising projects, reallocating unused funds from the "Luoyang Lihua Breeding Farm Project" to the "Yangzhou Lihua Poultry Breeding Project" [5]. - The completion dates for several poultry slaughtering projects were adjusted to December 31, 2023, to align with actual construction progress [5]. Group 5: Fund Management and Review - The sponsor reviewed the management and usage of the raised funds, confirming compliance with relevant regulations and proper storage in dedicated accounts [9]. - As of December 31, 2024, all raised funds have been fully utilized and the accounts closed [9].

Group 1 - Since April, the global capital markets have experienced significant volatility, with the A-share market showing recovery after a sharp decline on April 7. Sectors such as leisure food, general retail, beverage and dairy, and agriculture have seen cumulative gains exceeding 11% since April, marking them as bright spots in the market [1] - Multiple brokerage research teams have actively provided professional analysis and macroeconomic outlooks, indicating a strong belief that the upward trend in the Chinese stock market is far from over [1][2] - Central Huijin's liquidity support for stabilizing the stock market has been emphasized, with analysts expressing confidence in the government's commitment to maintaining market stability [2] Group 2 - Analysts predict that the funding environment will remain relatively loose in May, primarily driven by medium to long-term capital entering the market. The focus will shift to technology, green sectors, consumption, and infrastructure in the medium term [3] - The performance of recommended stocks by brokerages has been closely monitored, with 43 brokerages recommending 265 stocks in April, of which 120 stocks outperformed the Shanghai Composite Index, representing 45.28% [5] - Notably, three stocks have seen gains exceeding 50% in April, with Wanchen Group leading at 53.11%, followed by Kexing Pharmaceutical at 52.99%, and Xianda Co. at 51.76% [5][6] Group 3 - The most recommended stock in April was Qingdao Beer, which was recommended by nine brokerages, showing a modest gain of 1.51%. In contrast, Gree Electric, recommended by seven brokerages, experienced a slight decline of 0.53% [6] - The brokerage stock combination index reflects the "mining" capability of brokerage research teams, with only ten brokerage stock combination indices showing an increase since April [6]

Core Viewpoint - The company, Saintno Biopharmaceuticals (688117), reported a mixed financial performance for 2024 and the first quarter of 2025, with significant growth in Q1 2025 driven by increased sales of specific products, while facing challenges in overall profitability due to rising R&D costs [2][6]. Financial Performance - In 2024, the company achieved operating revenue of 456.07 million yuan, a year-on-year increase of 4.84% [2] - The net profit attributable to the parent company, excluding non-recurring gains and losses, was 45.61 million yuan, a decrease of 24.24% year-on-year [2] - For Q1 2025, the company reported operating revenue of 184.34 million yuan, a significant year-on-year increase of 77.15% [2] - The net profit attributable to the parent company for Q1 2025 was 47.12 million yuan, reflecting a year-on-year increase of 186.06% [2] R&D Progress - The company has made advancements in several R&D projects, including the approval of various raw materials and the establishment of a joint research center with Zhejiang University [3][6] - In 2024, the company invested 50.46 million yuan in R&D, representing 11.06% of its operating revenue, which is a 45.05% increase compared to the previous year [2] Overseas Market Strategy - The company plans to enhance its overseas sales strategy by building a professional sales and marketing team to improve market expansion and brand development [4] - An investment agreement was signed with Africa Bio Chem Co. Ltd in Tanzania for 30 million yuan, acquiring a 22.78% stake to strengthen its overseas presence [4] Capacity Expansion - The company is actively advancing several capacity expansion projects, including a production line for polypeptide raw materials and a technology transformation project for formulations [5] - The production line project has entered the validation stage, and the company aims to meet the growing customer demand through these expansions [5] Market Sentiment - Recently, one institution has given a buy rating for the stock, indicating positive market sentiment [7] - The stock has seen a net inflow of 59.1 million yuan in financing over the past three months, suggesting increased investor interest [8]

中国经济网北京4月25日讯神农集团（605296）(605296.SH)披露公告，公司于2025年4月24日收到上海证券交易所就公司2024年 度以简易程序向特定对象发行A股股票事项申请的审核意见："根据《证券法》《上市公司证券发行注册管理办法》《上海证券 交易所上市公司证券发行上市审核规则》等有关法律、法规及本所有关规定，云南神农农业产业集团股份有限公司以简易程序 向特定对象发行股票申请符合发行条件、上市条件和信息披露要求。本所将在收到你公司申请文件后提交中国证监会注册。" 神农集团本次向特定对象发行股票事项尚需获得中国证监会作出同意注册的决定，最终能否获得中国证监会同意注册的决定及 时间尚存在不确定性。公司将根据进展情况，严格按照上市公司向特定对象发行股票相关法律法规的要求及时履行信息披露义 务，请广大投资者注意投资风险。 根据本次发行的竞价结果，发行对象拟认购金额合计为29,000.00万元，扣除相关发行费用后的募集资金净额将全部用于红河弥 勒神农畜牧有限公司五山乡年出栏24万头优质仔猪扩繁基地建设项目、云南神农集团石林畜牧有限公司林口铺养殖场生物安全 升级技改建设项目、产业链数字化智能化建设项目、补充 ...